WALTHAM, Mass.--(EON: Enhanced Online News)--N-of-One, Inc., the leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, presented data at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference identifying additional treatment options beyond the standard of care for some patients with unexpected genetic alterations.
“The availability of a molecularly targeted treatment can have significant impact for affected patients.”
The data showed that ERBB2 amplification, a known alteration commonly found in breast and gastric cancers and treated with a targeted monoclonal antibody, as well as ERBB2 mutations, were found in a small percentage of at least ten other types of cancers from among the 4,000 patient tumors the company has analyzed.
N-of-One, a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options delivered to the point of care. These therapeutic options include both approved therapies and therapies in clinical trials, and all reports are specifically targeted to each patient’s tumor’s molecular profile.
“When an unexpected alteration is discovered in a tumor, N-of-One’s interpretation provides the patient’s oncologist with additional treatment options that otherwise may not have been considered,” said Jennifer Levin Carter MD, MPH, founder and Chief Medical Officer of N-of-One. “The availability of a molecularly targeted treatment can have significant impact for affected patients.”
The N-of-One data presented at the AACR-NCI-EORTC meeting showed that while ERBB2 amplification is common in breast cancer, ERBB2 mutations have been documented in a percentage of other cancers, including:
- 4% (17/386) of lung adenocarcinoma
- 3% (3/101) of melanoma
- 4% (4/94) of cholangiocarcinoma
- 2% (6/271) of colorectal adenocarcinoma
“These findings suggest that there are populations of patients with many different types of cancer that may benefit from treatment with trastuzumab or other ERBB2 inhibitors that are currently used to treat patients with breast and gastroesophageal cancers with ERBB2 alterations,” said Sheryl Elkin, PhD, Scientific Director of N-of-One, who presented the data. “Our results illustrate that additional research into the role of ERBB2 alterations and associated therapeutic strategies across cancer types is warranted, and that there is significant opportunity to identify additional targets and treatment strategies for cancer patients through next generation sequencing and clinical interpretation.”
N-of-One, a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options focused on the point of care. Using the company’s PrecisionWorks™ knowledge integration platform and framework, N-of-One’s team of experts has delivered more than 4,000 personalized, interpretative roadmaps to oncologists and patients worldwide, through partnerships to provide interpretation services for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists or through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.